Generated by AI
GH Research PLC is a clinical-stage biopharmaceutical company focused on developing treatments for psychiatric and neurological disorders, with an initial emphasis on depression and treatment-resistant depression. Its current pipeline centers on mebufotenin-based therapies, including GH001, an inhalable product candidate being studied for treatment-resistant depression, bipolar II disorder, and postpartum depression, and GH002, an intravenous candidate in early clinical development. The company is centered on research and development and works to advance novel therapeutic options for mental health conditions with significant unmet medical need. Based in Dublin, Ireland, GH Research PLC is positioned in the broader healthcare and biotechnology markets as a specialist developer of psychedelic-inspired medicines.
WebsiteJoshua Dawson House
Dublin, D02 RY95
Ireland
The latest articles about GHRS.
Novel GH001 Aerosol Delivery System (ADS) device: final results of the GH001-HV-106 trial support going from 3 → 1 doses per treatment visitTRD pivotal program — positive initial feedback from FDA, End-of-Phase 2 meeting expected in Q1 2027, initiation shortly afterPPD pivotal program — initiation targeted for H2 2027Vanina Popova, MD, appointed Chief Development Officer — Formerly Clinical Development at J&J, lead author of pivotal Spravato® trial publicationCash, cash equivalents and marketabl
Summary of Nov 18's posts. Generated by AI.
Summary of Jan 8's posts. Generated by AI.
Summary of Apr 20's posts. Generated by AI.
Summary of Nov 16's posts. Generated by AI.
Investors talking about GHRS also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.